Efficacy And Safety of Myo Inositol in The Treatment of Polycystic Ovary Syndrome Patients Comparison with Metformin

  • Mst. Ahsana Akter
  • Karmoker CR Medical Officer, UHC, Charghat, Rajshahi, Bangladesh
  • Khatun A Medical Officer, Chapainawabganj Sadar Hospital, Chapainawabganj, Bangladesh
  • Sarkar AC ICU Specialist, Lab Aid Cardiac Hospital, Dhaka, Bangladesh
Keywords: Myo Inositol, Polycystic Ovary Syndrome, Metformin

Abstract

Background: In polycystic ovary syndrome (PCOS), changes in physical appearancei.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. Metformin and Myo-inositol being insulin sensitizers improve biochemical, clinical and reproductive parameters in PCOS women. This study was done to compare the efficacy and safety of Myo- inositol versus Metformin among PCOS women.

Methodology: This open labeled randomized control trial was conducted over aperiod of 1 years in the Department of Gynecology & Obstetrics, Rajshahi Medical College Hospital, Rajshahi. Total 100 women with polycystic ovarian syndrome were enrolled and randomly (by simple lottery method) divided into two treatment groups: group A (Tab Myo-inositol 1g twice daily for 6 months) and group B (Tab. Metformin 500 mg thrice daily for 6 months). After taking informed consent, by face-to-face interview baseline data will be collected consecutively from polycystic ovarian syndrome women with the help of a semi-structured questionnaire. Both groups were followed up at the end of third and six months of whole drug therapy period. The data were analyzed via SPSS (version 24.0).

Results: Mean age of all study subjects was 24.24±3.47 SD (years). Both groups were statistically comparable regarding sociodemographic profile, baseline clinical and biochemical variables (p>0.05). Mean Ferriman-Gallwey score and Luteinizing hormone was higher among group B than group A at the end of 6 months (p<0.05). After 6 months of treatment, regular menstrual cycles increased by 38% and 26% (p>0.05) while acne reduced by 26% and 14% in group A and B respectively (p=0.021). Vomiting, generalized weakness, flatulence was significantly higher in metformin group than myo-inositol group after 6 months (p<0.05).

Conclusion: In the treatment of PCOS patients, myo-inositol is as effective as metformin and has a better safety profile. However, further larger multicenter studies are warranted.

Downloads

Download data is not yet available.

Author Biography

Karmoker CR, Medical Officer, UHC, Charghat, Rajshahi, Bangladesh

Medical Officer

References

1. Rani, D.M. & Singh, P.D.M., 2019. A Study on the efficacy and safety of Myoinositol and Metformin in the treatment of PCOS. Journal of Medical Science And clinical Research, 7(5), 712–716.
2. Merkin, S.S., Azziz, R., Seeman, T., Calderon-Margalit, R., Daviglus, M., Kiefe, C., et al., 2011. Socioeconomic Status and Polycystic Ovary Syndrome. Journal of Women’s Health, 20(3), 413–419.
3. Angik, R., 2015. A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: a randomised controlled trial. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 4(1), 1-21.
4. Anu, M., Saraswathi, K., Elizabeth, P. & David, J., 2021. A Comparative Study of Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. 25(3), 3770–3783.
5. Badawy, A. & Elnashar, A., 2011. Treatment options for polycystic ovary syndrome.
6. International Journal of Women’s Health, 3(1), 25–35.
7. Baillargeon, J.P., Iuorno, M.J. & Nestler, J.E., 2003. Insulin sensitizers for polycystic ovary syndrome. Clinical Obstetrics and Gynecology, 46(2), 325–340.
8. Nehra, J., Kaushal, J., Singhal, S.R. & Ghalaut, V.S., 2017. Comparision Of Myo- Inositol Versus Metformin On Anthropometric Parameters In Polycystic Ovarian Syndrome In Women. International Journal of Pharmacy and Pharmaceutical Sciences, 9(4), 144–148.
9. Hussein, B. & Alalaf, S., 2013. Prevalence and characteristics of polycystic ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility center in maternity teaching hospital of Erbil City. Open Journal of Obstetrics and Gynecology, 03(07), 577–585.
10. Costantino, D., Minozzi, G., Minozzi, F. & Guaraldi, C., 2009. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: A double-blind trial. European Review for Medical and Pharmacological Sciences, 13(2), 105–110.
11. Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., et al., 2017a. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology, 86(5), 725–730.
12. Mahdi, S.H.A., Siddiqua, F., Mohol, M., Chakrabarty, S. & Hossain, M.G., 2018. Effect of Socio-demographic , Clinical and Hormonal Factors on Polycystic Ovarian Syndrome ( PCOS ) among the Infertile Women : A Hospital-based Study in Rajshahi, Bangladesh. Human Biology Review, 7(Issn 22774424), 226–235.
13. Hussein, B. & Alalaf, S., 2013. Prevalence and characteristics of polycystic ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility center in maternity teaching hospital of Erbil City. Open Journal of Obstetrics and Gynecology, 03(07), 577–585.
14. Ishak, A., Kadir, A.A., Hazlina, N., Hussain, N. & Bahari, S., 2012. Prevalence and Characteristics of Metabolic Syndrome among Polycystic Ovarian Syndrome Patients in Malaysia. International Journal of Collaborative Research on Internal Medicine & Public Health, 4(8), 1577–1588.
15. Dhagat, V., Shah, P., Thakar, R. & Deliwala, K., 2013. Study of 100 cases of Infertility in Polycystic ovarian syndrome and its management outcome. International Journal of Medical Science and Public Health, 2(4), 1041.
16. Himabindu, Y., Sriharibabu, M. & Surekha, T., 2013. Impact of socio-economic status on ovarian reserve markers. Journal of Human Reproductive Sciences, 6(3), 201.
17. Himabindu, Y., Sriharibabu, M. & Surekha, T., 2013. Impact of socio-economic status on ovarian reserve markers. Journal of Human Reproductive Sciences, 6(3), 201.
18. Le Donne, M., Alibrandi, A., Giarrusso, R., Lo Monaco, I. & Muraca, U., 2012. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva ginecologica, 64(1), 23–9.
19. Cheang, K.I., Huszar, J.M., Best, A.M., Sharma, S., Essah, P.A. & Nestler, J.E., 2009. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diabetes and Vascular Disease Research, 6(2), 110–119.
20. Maria Concetta Musacchio, V.D.L., 2013. A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients. Journal of Metabolic Syndrome, 02(02), 1-22.
21. De Leo, V., La Marca, A. & Petraglia, F., 2003. Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocrine Reviews, 24(5), 633–667.
22. Nabi, S. & Guleria, R., 2020. Comparison of Myoinositol and Metformin in Women with Polycystic Ovarian Syndrome. Clini Cal Study, 30(11), 1045–1049.
23. Ranwa, M., Nagaria, T., Jaiswal, J. & Arya, A., 2017. Study of effect of myoinositol on menstrual irregularities and skin problems in polycystic ovarian syndrome cases. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6(6), 2310.
24. Chirania, K., Misra, S. & Behera, S., 2017. A randomised clinical trial comparing myoinositol and metformin in PCOS. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6(5), 1814.
25. Nazari, T., Bayat, R. & Hamedi, M., 2007a. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. Archives of Iranian medicine, 10(2), 176–81.
26. Nazari, T., Bayat, R. & Hamedi, M., 2007a. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. Archives of Iranian medicine, 10(2), 176–81.
27. Zacchè, M.M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M. & Ferrari, A., 2009. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecological Endocrinology, 25(8), 508–513.
28. Ranwa, M., Nagaria, T., Jaiswal, J. & Arya, A., 2017. Study of effect of myoinositol on menstrual irregularities and skin problems in polycystic ovarian syndrome cases. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6(6), 2310.
29. Carlomagno, G. & Unfer, V., 2011. Inositol safety: Clinical evidences. European Review for Medical and Pharmacological Sciences, 15(8), 931–936.
30. Sanoee, M.F., Neghab, N., Rabiee, S. & Amiri, I., 2011. Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome. Iranian Journal of Medical Sciences, 36(2), 90–95.
How to Cite
Mst. Ahsana Akter, Karmoker, C. R., Khatun, A., & Sarkar, A. C. (2025). Efficacy And Safety of Myo Inositol in The Treatment of Polycystic Ovary Syndrome Patients Comparison with Metformin. Obs Gyne Review: Journal of Obstetric and Gynecology, 11(1), 10 - 20. Retrieved from https://obstetrics.medresearch.in/index.php/joog/article/view/180
Issue
Vol 11 No 1 (2025): Jan-Dec
Section
Original Article

Copyright (c) 2025 Author (s). Published by Siddharth Health Research and Social Welfare Society

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.